Yili Chuanning Biotechnology News

Twining Biotech (301301): Continued high growth in performance, expected to increase the contribution of synthetic biological varieties

Aug 29 17:06

Twining Biotech (301301) 2024 Semi-Annual Report Review: Reoptimizing the leading intermediate pattern, the company's performance continues to grow at a high rate

Aug 27 11:11

Twining Biotech (301301): Outstanding performance, the antibiotic intermediate boom is expected to continue

Jul 8 18:51

Dongwu Securities released a research report on April 28 stating that it gave Channing Biotech (301301.SZ) a purchase rating. The main reasons for the rating include: 1) performance is accelerating quarterly, and I am optimistic that the company's profita

Zhitong FinanceApr 28 14:56

Twining Biotech (301301): Performance exceeds expectations, high demand for intermediates supports high performance growth

Apr 26 00:00

Twining Biotech (301301): Performance continues to exceed expectations, the volume and price of core products rise sharply & reduce costs and increase efficiency

Apr 24 07:26

SDIC Securities released a research report on April 14 stating that it gave Channing Biotech (301301.SZ) a purchase rating. The main reasons for the rating include: 1) efficient collaboration between technology platforms and industrialization bases to con

Zhitong FinanceApr 14 09:22

Twining Biotech (301301): Profits continue to be released, synthetic biology empowers long-term growth

Apr 13 00:00

Tuan Ning Biology (301301) 2023 Quarterly Report Review: Q3 Performance Exceeded Expectations, New Products Begin Contributing to Revenue

Oct 25, 2023 16:12

Tuan Ning Biology (301301): Profit continues to be released, focusing on the implementation of synthetic biological varieties

Oct 24, 2023 16:36

Twining Biology (301301): Steady growth of intermediates and gradual implementation of synthetic biology pipelines

中信建投證券Aug 28, 2023 15:42

Twinings Biology (301301): Performance slightly exceeds expectations, synthetic biology pipeline is progressing steadily

東吳證券Aug 23, 2023 18:22

Twinning Biotech (301301): Traditional Businesses Accelerate Resumption of Synthetic Biology to Empower High Growth in the Future

東吳證券(國際)Jan 5, 2023 00:00

Twinning Biotech (301301): Traditional Businesses Accelerate Resumption of Synthetic Biology to Empower High Growth in the Future

東吳證券Dec 26, 2022 00:00

Twinning Biotech (301301) IPO Coverage Study

華金證券Dec 7, 2022 00:00